← Back to all trials
Recruiting
NCT05858619
Molecular Signatures of Cutaneous Dupilumab Response
Conditions: Atopic Dermatitis
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE4
Enrollment: 15
Sponsor: University of California, San Francisco
Location: University of California, San Francisco San Francisco California
Summary
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Eligibility Criteria
Inclusion Criteria:
1. 18 years of age or older
2. atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7
Exclusion Criteria:
1. Known pregnancy
2. Known immunodeficiencies
3. Known parasitic infection -
Source: ClinicalTrials.gov (NCT05858619). StuddyBuddy aggregates publicly available trial information.
